Phase II clinical trial of neuroprotection by cannabinoids in Huntington disease.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Nabiximols (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SAT-HD
- 30 Dec 2011 GW Pharmaceuticals added as trial sponsor as reported by ClinicalTrials.gov.
- 30 Dec 2011 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Planned end date changed from 5 Apr 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.